BioMimetic Therapeutics, Inc. to Highlight Clinical and Preclinical Activities at ORS and AAOS Meetings
Franklin, Tenn. – February 29, 2008 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company will present data next week at the Orthopedic Research Society (ORS) and the American Academy of Orthopedic Surgeons (AAOS) meetings, highlighting its pre-clinical and clinical studies in the orthopedic space. These meetings are being held consecutively in San Francisco, CA the week of March 2, 2008.
The following posters will be presented at the ORS Meeting at various times between March 2 and March 4, 2008 on Level Three of the Moscone West Convention Center in San Francisco:
-Poster # 316 :: rhPDGF-BB Enhances Rotator Cuff Tendon Healing in Sheep Model
-Poster #876 :: rhPDGF-BB Augmentation of New Bone Formation in a Rat Model of Distraction Osteogenesis
-Poster #963 :: Percutaneous Injection of GEM OS2, a Combination of rhPDGF-BB and Bovine Type I Collagen/Beta Tricalcium Phosphate Matrix Increases Vertebral Bone Mineral Density in Geriatric Female Baboons
-Poster # 988 :: Stimulation of Fracture Healing by Recombinant Human Platelet Derived Growth Factor-BB combined with Beta Tricalcium Phosphte/Collagen Matrix in a Diabetic Rat Fracture Model
-Poster #1479 :: Evaluation of Recombinant Human Platelet Derived Growth Factor-BB Combined with Collagen Matrix as a Device for Tendon Repair
-Poster # 1498 :: PDGF Induces Cell Proliferation and Angiogenesis in a Rat Rotator Cuff Repair Model of Tendon-Bone Healing
-Poster #1693 :: Release, Potency and Stability of Clinical Formulations of Recombinant Human Platelet Derived Growth Factor-BB (rhPDGF-BB) Combined with Two Osteoconductive Materials: GEM OS1 and GEM 21S®
Additionally, there will be two podium presentations during the AAOS Meeting focusing on the use of rhPDGF-BB:
-Dr. Michael Ehrlich will present rhPDGF-BB Increases New Bone Formation in a Rat Model of Distraction Osteogeneis during the Pediatrics 1: General, Upper Extremity and Spine Session. Dr. Ehrlich's presentation will take place on Thursday, March 6 at 8:00 a.m. PT at Podium 181 at the Moscone Convention Center in room 307 – 310.
-Dr. Christopher DiGiovanni will present A Human Feasibility Trial Evaluating rhPDGF vs. Autologous Bone Graft during Foot and Ankle Fusion during the Foot/Ankle 1: Arthroplasty and Arthrodesis Session. Dr. DiGiovanni's presentation will take place on Thursday, March 6 at 10:54 a.m. PT at Podium 259 at the Moscone Convention Center in room 250 – 262.
The Company will also host an investor and analyst meeting to discuss pre-clinical and clinical data presented at the ORS and AAOS meetings. The program will also focus on new clinical opportunities and will provide updates on the Company's clinical pipeline. The meeting will take place on Thursday, March 6 at 5:00 PT at One Bush Street, 17th Floor, San Francisco, 94104.
In addition to the presentations being held at ORS and AAOS, Dr. Charles Hart, chief scientific officer, will provide an update of corporate activities at the Canaccord Adams Small Cap Orthopedics Conference. The presentation will take place at the Mission Bay Conference Center in San Francisco on Tuesday, March 4 at 1:10 p.m. PT. A live audio webcast of the presentation will be available at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2186580 and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS1 and GEM OS2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's previously approved product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
GEM 21S® is a registered trademark of Luitpold Pharmaceuticals, Inc., who owns and markets that product through its Osteohealth Company division.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, associate director of corporate communications, at 615-236-4419.
Back to Headlines |
